Strong Q3; guidance upgrade driven by FX
08/11/19 -"Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating ..."
Pages
42
Language
English
Published on
08/11/19
You may also be interested by these reports :
18/11/19
The growth momentum in two (Healthcare and Life Science) out of the three divisions accelerated in Q3 and this is expected to continue (in Life ...
14/11/19
Merck’s profitability was materially driven by Healthcare, which generated strong organic growth and the profitability line was additionally helped ...
12/11/19
We have not heard a lot from Lonza in 2019, but the second CEO ‘disposal’ within a ten-month period looks quite strange to us. This is very atypical ...
11/11/19
Since we last pushed Novartis’ (ADD, Switzerland) investment story – “Novartis’ rejuvenation lacks speed” – in January 2018, the stock did well, ...